myelofibrosis, polycythemia vera, acute graft versus host disease, chronic graft versus host disease
Haematology · 2026–2026
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ruxolitinib Expansion of prescriber type to nurse practitioners (NPs) for existing PBS-listed ruxolitinib in myelofibrosis (MF), polycythemia vera (PV), acute… | Mar 2026 | Recommended with restriction | input received |
What the PBS pays
$113M in government benefit over 2024–25, across 24,899 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ruxolitinib | $113.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.